Skip to content

A comparative study on the analgesic effect, safety and efficacy of bupivacaine liposome local infiltration and sufentanil PCIA after lobectomy of the lung

A comparative study on the analgesic effect, safety and efficacy of bupivacaine liposome local infiltration and sufentanil PCIA after lobectomy of the lung

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117393
Enrollment
Unknown
Registered
2026-01-23
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain

Interventions

Bupivacaine liposome local infiltration group:Bupivacaine liposome local infiltration
Sufentanil PCIA group:Sufentanil PCIA

Sponsors

Henan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age range: 18 - 75 years old; 2.ASA classification levels I-III; 3.Planning to undergo elective lobectomy of the lung; 4.Sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Allergic to bupivacaine or sufentanil; 2.Severe liver and kidney dysfunction (Child-Pugh C grade or eGFR 3 months); 4.There was a chronic pain syndrome prior to the surgery. 5.Unable to cooperate with postoperative analgesia assessment (such as cognitive impairment);

Design outcomes

Primary

MeasureTime frame
The pain scores measured at rest and during coughing within 48 hours after the operationThe pain scores at rest and during coughing within 48 hours after the operation;

Secondary

MeasureTime frame
Total dosage of analgesic drugs;Incidence of adverse reactions (such as nausea, vomiting, respiratory depression, local infection, etc.);Patient satisfaction score (assessed using the Likert 5-point scale: 1 = very dissatisfied, 5 = very satisfied);Postoperative recovery status;

Countries

China

Contacts

Public ContactLyu Shuaiguo

Henan Cancer Hospital

lvshuaiguo1981@126.com+86 371 65588329

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026